| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Narinder Pal Bhalla is Chief Medical Officer at LXEO. Narinder Pal Bhalla's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $264K at current prices.
The LXEO filings lean toward selling, a net 22,306 shares.
Narinder Pal Bhalla has 3 Form 4 filings on record from February 2026 to September 2026, all as Chief Medical Officer at Lexeo Therapeutics (LXEO), 2026.
The 6 reported transactions were 3 stock awards, 2 option or other derivative awards and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $99K.
The only open-market sale was 22,306 shares of LXEO at an average $4.42 on July 1, 2026, about $99K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | LXEO Lexeo Therapeutics, Inc. | Chief Medical Officer | Sell | 22,306 | $4.42 | $98,592.52 | -21.3% | -23.1% | - |